Intralesional PV‐10 for in‐transit melanoma—A single‐center experience

Abstract

PV-10 is an effective, durable, well-tolerated treatment tool with an acceptable side effect profile for the management of unresectable in-transit melanoma. J. Surg. Oncol. 2016;114:380-384. © 2016 Wiley Periodicals, Inc.

Intralesional PV‐10 for the treatment of in‐transit melanoma metastases—Results of a prospective, non‐randomized, single center study

“…With multiple, consecutive interventions, the ORR increased to 86.6% (CR 42.2%, PR 44.4%) and the mean PFS duration was 5.0 months. These results complement both the Phase II results (ORR 71% with all treated lesions) and a parallel study where the ORR was 52% . The findings also corroborate the Phase I study results where the complete response rate was 27% and ORR was 55%, with a median follow‐up duration of 28 months …”

“…In‐transit melanoma is often characterized by a poly‐recurrent pattern of disease progression with variable treatment responses and considerable morbidity. Intralesional PV‐10 has previously been reported as a successful therapy for patients with stage III and IV melanoma (Supplementary Table S1) . This prompted further investigation into predictors of treatment response in order to improve patient selection.…”

“…In a multi‐center Phase II trial of 80 patients with Stage III‐IV melanoma, PV‐10 treatment produced a 51% overall response rate (ORR) and complete response (CR) in 50% when all disease was injected . In another case series, IL PV‐10 yielded an ORR of 52%, a complete response rate of 26% and bystander response in 50% of patients with non‐target lesions . Based on this clinical evidence, PV‐10 treatment was continued at our institution after the completion of the Phase II trial, using the existing trial protocol in a selected cohort of patients.…”

Potassium iodide potentiates antimicrobial photodynamic inactivation mediated by Rose Bengal: in vitro and in vivo studies

“…It is used as a stain to identify corneal damage (10), in the diagnosis of brucellosis (11), and as a PS to mediate photochemical tissue bonding (12). It has also been used as an anticancer compound (in the dark) given as an intralesional injection into transit melanoma metastases, where it has been shown to activate an antitumor immune response (13). When used as an antimicrobial PS, RB has been found to have a major effect against Gram-positive bacteria and is also effective against fungi, such as Candida spp., but its activity against Gram-negative bacteria is minimal.…”

A systematic review and meta‐analysis of locoregional treatments for in‐transit melanoma

“…Table summarizes the key data for each modality and presents the pooled results including the weighted ORR and meta‐analysis data. Assessed studies included: randomized controlled trials, nonrandomized phase I and II comparative and noncomparative studies, and prospective or retrospective case series (NHMRC levels II–IV evidence; Tables S2‐S9) . Only two therapies: amputation and topical imiquimod, were suitable for formal meta‐analysis ( I 2 value ≤ 40%).…”